Cited by 1,493Adipokines, Inflammation, and Metabolic DiseasesDiabetes, Cardiovascular Risks, and LipoproteinsCytokine Signaling Pathways and Interactions

Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes

Open access
Spranger, Joachim, Kroke, Anja, Möhlig, Matthias, Hoffmann, Kurt, Bergmann, Manuela M., Ristow, Michael, Boeing, Heiner, Pfeiffer, Andreas F.H.·2003·Diabetes

Abstract

A subclinical inflammatory reaction has been shown to precede the onset of type 2 (non-insulin-dependent) diabetes. We therefore examined prospectively the effects of the central inflammatory cytokines interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) on the development of type 2 diabetes. We designed a nested case-control study within the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study including 27,548 individuals. Case subjects were defined to be those who were free of type 2 diabetes at baseline and subsequently developed type 2 diabetes during a 2.3-year follow-up period. A total of 192 cases of incident type 2 diabetes were identified and matched with 384 non-disease-developing control subjects. IL-6 and TNF-α levels were found to be elevated in participants with incident type 2 diabetes, whereas IL-1β plasma levels did not differ between the groups. Analysis of single cytokines revealed IL-6 as an independent predictor of type 2 diabetes after adjustment for age, sex, BMI, waist-to-hip ratio (WHR), sports, smoking status, educational attainment, alcohol consumption, and HbA1c (4th vs. the 1st quartile: odds ratio [OR] 2.6, 95% CI 1.2–5.5). The association between TNF-α and future type 2 diabetes was no longer significant after adjustment for BMI or WHR. Interestingly, combined analysis of the cytokines revealed a significant interaction between IL-1β and IL-6. In the fully adjusted model, participants with detectable levels of IL-1β and elevated levels of IL-6 had an independently increased risk to develop type 2 diabetes (3.3, 1.7–6.8), whereas individuals with increased concentrations of IL-6 but undetectable levels of IL-1β had no significantly increased risk, both compared with the low-level reference group. These results were confirmed in an analysis including only individuals with HbA1c <5.8% at baseline. Our data suggest that the pattern of circulating inflammatory cytokines modifies the risk for type 2 diabetes. In particular, a combined elevation of IL-1β and IL-6, rather than the isolated elevation of IL-6 alone, independently increases the risk of type 2 diabetes. These data strongly support the hypothesis that a subclinical inflammatory reaction has a role in the pathogenesis of type 2 diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diabetes.52.3.812

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Acute phase reactants and proinflammatory cytokines, such as CRP and IL-6, predict the development of T2DM in addition to the risk of complications.

    “Furthermore, acute phase reactants and proinflammatory cytokines, such as C-reactive protein (CRP) and interleukin-6 (IL-6) predict the development of T2DM in addition to the risk of complications. 3,4”

    From <scp>Glucagon‐like peptide‐1 receptor agonists</scp> improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials (2021) · cites this paper as [3]

    The Clinical parameters section reports that elevated CRP was associated with increased risk of developing type 2 diabetes, and the Abstract identifies IL-6 as an independent predictor. The Discussion qualifies the IL-6 finding: elevated IL-6 alone, without detectable IL-1β, did not substantially increase risk. The paper does not report whether CRP or IL-6 predicts the risk of diabetes complications. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Accumulating evidence suggests that a subclinical inflammatory reaction participates in the pathogenesis of T2DM and its cardiorenal complications, with elevated plasma levels of pro-inflammatory cytokines.

    “Accumulating evidence suggests that a subclinical inflammatory reaction participates in the pathogenesis of T2DM and its cardiorenal complications, with elevated plasma levels of pro-inflammatory cytokines, including tumour necrosis factor-alpha (TNF-α), 11 interleukin-1 beta (IL-1β), 12 IL-6 13,14 and other IL-1-dependent pro-inflammatory cytokines and chemokines.[15][16][17][18]”

    From The effect of <scp>GLP</scp> ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis (2025) · cites this paper as [12]

    The Abstract reports that a subclinical inflammatory reaction may contribute to type 2 diabetes and links circulating IL-6 and IL-1β patterns to future diabetes risk. The paper does not address cardiorenal complications or establish that all the listed cytokines are individually elevated: its Results report no significant difference in IL-1β levels between cases and controls. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Case-control studies have found that elevated IL-6 and combined elevation of IL-6 and IL-1β are independent predictors of diabetes.

    “Case-control studies have found that elevated IL-6 and the combined elevation of IL-6 and IL-1β, both SASP factors, are independent predictors of diabetes (55,56).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Spranger, J., Kroke, A., Möhlig, M., Hoffmann, K., Bergmann, M. M., Ristow, M., Boeing, H., & Pfeiffer, A. F. H.
Affiliations
  • German Institute of Human Nutrition (DE)
  • Department of Endocrinology, Diabetes and Nutrition, Benjamin Franklin Medical Center, Free University Berlin, Berlin, Germany
Venue
Diabetes
Published
2003-03-01
Volume
52
Issue
3
Pages
812-817
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2411826498
Cited by
1,493
References
25
Citations by year
2026: 23 · 2025: 48 · 2024: 75 · 2023: 64 · 2022: 69 · 2021: 80 · 2020: 79 · 2019: 78 · 2018: 72 · 2017: 65 · 2016: 90 · 2015: 85 · 2014: 96 · 2013: 75 · 2012: 70
FWCI
27.36
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly and Company
  • European Commission
  • Deutsche Forschungsgemeinschaft (1076/1)
  • Deutsche Krebshilfe
  • Universität Greifswald
Topics
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
Keywords
type 2 diabetes, inflammatory cytokines, interleukin-6, IL-1β, TNF-α, subclinical inflammation, diabetes risk, cytokine interactions, HbA1c, adiposity, waist-to-hip ratio, diabetes pathogenesis, biomarkers of disease risk, prospective cohort, nested case-control
MeSH terms
Adult, Aged, Blood Glucose, Body Constitution, C-Reactive Protein, Diabetes Mellitus, Type 2, Europe, Female, Glycated Hemoglobin, Humans, Inflammation, Interleukin-1, Male, Middle Aged, Neoplasms, Nutritional Physiological Phenomena, Prospective Studies, Risk Factors, Tumor Necrosis Factor-alpha, Exercise, Interleukin-6, Body Mass Index, Case-Control Studies, Cytokines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review